BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers

N/ACitations
Citations of this article
279Readers
Mendeley users who have this article in their library.
Get full text

Abstract

BACKGROUND. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 1 million deaths worldwide; thus, there is an urgent need to develop preventive and therapeutic strategies. The antituberculosis vaccine bacillus Calmette-Guérin (BCG) demonstrates nonspecific, protective innate immune-boosting effects. Here, we determined whether a history of BCG vaccination was associated with decreased SARS-CoV-2 infection and seroconversion in a longitudinal, retrospective observational study of a diverse cohort of health care workers (HCWs). METHODS. We assessed SARS-CoV-2 seroprevalence and collected medical questionnaires, which included information on BCG vaccination status and preexisting demographic and clinical characteristics, from an observational cohort of HCWs in a multisite Los Angeles health care organization. We used multivariate analysis to determine whether a history of BCG vaccination was associated with decreased rates of SARS-CoV-2 infection and seroconversion. RESULTS. Of the 6201 HCWs, 29.6% reported a history of BCG vaccination, whereas 68.9% had not received BCG vaccination. Seroprevalence of anti-SARS-CoV-2 IgG as well as the incidence of self-reported clinical symptoms associated with coronavirus disease 2019 (COVID-19) were markedly decreased among HCWs with a history of BCG vaccination compared with those without BCG vaccination. After adjusting for age and sex, we found that a history of BCG vaccination, but not meningococcal, pneumococcal, or influenza vaccination, was associated with decreased SARS-CoV-2 IgG seroconversion. CONCLUSIONS. A history of BCG vaccination was associated with a decrease in the seroprevalence of anti-SARS-CoV-2 IgG and a lower number of participants who self-reported experiencing COVID-19-related clinical symptoms in this cohort of HCWs. Therefore, large randomized, prospective clinical trials of BCG vaccination are urgently needed to confirm whether BCG vaccination can confer a protective effect against SARS-CoV-2 infection.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Rivas, M. N., Ebinger, J. E., Wu, M., Sun, N., Braun, J., Sobhani, K., … Arditi, M. (2021). BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. Journal of Clinical Investigation, 131(2). https://doi.org/10.1172/JCI145157

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 66

52%

Researcher 42

33%

Professor / Associate Prof. 11

9%

Lecturer / Post doc 7

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 51

43%

Immunology and Microbiology 24

20%

Biochemistry, Genetics and Molecular Bi... 22

19%

Nursing and Health Professions 21

18%

Article Metrics

Tooltip
Mentions
Blog Mentions: 4
News Mentions: 15
Social Media
Shares, Likes & Comments: 820

Save time finding and organizing research with Mendeley

Sign up for free